United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Diversified Trust Co

Diversified Trust Co lifted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 286.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,045 shares of the biotechnology company’s stock after acquiring an additional 3,740 shares during the period. Diversified Trust Co’s holdings in United Therapeutics were worth $1,159,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in UTHR. Compass Ion Advisors LLC increased its position in shares of United Therapeutics by 3.6% during the 1st quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 101 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in United Therapeutics by 14.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 3,291 shares of the biotechnology company’s stock worth $756,000 after acquiring an additional 413 shares during the period. New England Research & Management Inc. raised its position in United Therapeutics by 29.8% in the first quarter. New England Research & Management Inc. now owns 10,430 shares of the biotechnology company’s stock worth $2,396,000 after acquiring an additional 2,395 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in United Therapeutics by 85.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock valued at $594,000 after acquiring an additional 1,191 shares during the last quarter. Finally, Cardinal Capital Management lifted its holdings in United Therapeutics by 20.2% in the 1st quarter. Cardinal Capital Management now owns 9,955 shares of the biotechnology company’s stock valued at $2,287,000 after acquiring an additional 1,675 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $319.01 on Tuesday. The business’s 50-day moving average is $276.47 and its 200-day moving average is $244.40. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The company has a market capitalization of $14.15 billion, a price-to-earnings ratio of 15.08, a P/E/G ratio of 1.40 and a beta of 0.55. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $325.00.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the prior year, the business earned $4.86 EPS. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Co. will post 24.73 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $233.27, for a total transaction of $3,499,050.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,325.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $233.27, for a total transaction of $3,499,050.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,325.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,160.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 126,344 shares of company stock valued at $32,426,462. Insiders own 12.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, May 2nd. Oppenheimer increased their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Wells Fargo & Company lifted their target price on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, June 12th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 20th. Finally, The Goldman Sachs Group lifted their price target on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $312.22.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.